Prne
May 24th, 2009
GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that in the frame of the first International Thyroid Awareness Week, from May 25 to 31, the company in cooperation with Thyroid Federation International (TFI) will launch an awareness campaign, also supported by the European Thyroid Association (ETA) and the Latin American Thyroid Society (LATS), to raise awareness of thyroid dysfunctions and their consequences, in approximately 40 countries worldwide. Together with the international patient organization TFI, Merck Serono will provide information on these under-diagnosed diseases through professional educational sessions and distribution of information to the public. These materials will be distributed in several languages and are available online for download.
“There are millions of people around the world who may be suffering needlessly because they are unaware of the symptoms and impact of thyroid disorders. Since thyroid hormones regulate the metabolism, an overactive or underactive thyroid gland can produce a wide variety of symptoms; but more importantly is that left untreated these symptoms can potentially lead to life-threatening complications”, said Yvonne Andersson, President of TFI. “By raising awareness of the common signs and symptoms of thyroid dysfunctions, we want to encourage people to seek medical advice if they believe they might be at risk.”
Today, it is estimated that 300 million people suffer from thyroid dysfunctions and over half are presumed to be unaware of their condition. An under- or overactive thyroid (hypothyroidism and hyperthyroidism) may occur at any time in life. Women in particular are five to eight times more likely to be affected than men. If left untreated, both hypothyroidism and hyperthyroidism can lead to serious complications, among which are cardiovascular diseases. Untreated thyroid disorders can also affect both pregnant women and the developing fetus.
“Most thyroid diseases are life-long conditions affecting patients’ quality of life. However because symptoms may be mild or non-specific, such as tiredness, weight gain, intolerance to cold or even depression, diagnosis is often missed or delayed”, said Dr. Richard Douge, Executive Vice President Global Marketing at Merck Serono. “However thyroid dysfunctions can be easily detected through a blood test and successfully managed with medical care”.
Merck Serono has a longstanding commitment to the treatment of thyroid diseases dating back to 1894 when its first thyroid medicine was launched. Today the company markets Euthyrox(R) (levothyroxine sodium) and Novothyral(R) (levothyroxine sodium, liothyronine sodium) for the treatment of hypothyroidism, Thyrozol(R) (thiamazole) for hyperthyroidism, Jodid(TM) (potassium iodide) for iodine deficiency (a cause of enlargement of the thyroid gland leading to goiter) and Jodthyrox(R) (levothyroxine sodium and potassium iodide) for the treatment of goiter. In 1994, with the support of the International Council for the Control of Iodine Deficiency Disorders (ICCIDD), the International Children’s fund (UNICEF) and the World Health Organization (WHO), the company contributed to the first international survey on the prevalence of iodine deficiency using the company’s emblematic ThyroMobil, a mobile van equipped with an ultrasound scanner for thyroid screening, to collect data among the population on four continents. Currently, Merck Serono has launched an educational campaign in China and intends to support an epidemiological project to shed light on the prevalence of thyroid disorders in China.
More information on thyroid disorders and their impact on patients’ life are available on: www.thyroidweek.com
About the Thyroid Federation International (TFI)
The Thyroid Federation International first convened in Toronto at the 11th International Thyroid Congress in September 1995. Diana Meltzer Abramsky, who in 1980 founded the Thyroid Foundation of Canada in Kingston, Ontario Canada, first advocated the vision of a world thyroid patient organization to deal with the problems of thyroid disease in a global perspective. Since then the Federation has grown to include thyroid organizations in many parts of the world, including Europe, North and South America, Australia and Japan.
TFI is an independent, worldwide network of patient-support organizations. The Federation works together for the benefit of those affected by thyroid disorders by providing information and raising awareness, by encouraging and assisting the formation of patient-oriented groups, and by working closely with the medical professions. TFI has a Medical Advisory Board, which consists of some of the most eminent thyroid specialists in the world.
For more information, please visit www.thyroid-fed.org
About Merck Serono
Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.
Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R) and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R), bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in all markets.
With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.
About Merck
Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32,700 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merck.de
Source: Merck Serono S A
Merck Serono: Media Relations, Tel.: +41-22-414-36-00
Filed under Business, Health, Health Care / Hospitals, Pharmaceuticals, Trade Show | Tags: australia, Europe, Geneva, May 25, Merck Serono S A, Switzerland | Comment Below
Related Press Releases Merck Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United StatesSeptember 29th, 2009 GENEVA - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies. /C O R R E C T I O N -- Merck Serono S A/September 15th, 2009 GENEVA - In the news release, "Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan" issued on 16 Sep 2009 07:00 GMT, by Merck Serono S A SWX:SEO over PR Newswire, we are advised by a representative of the company that the last sentence of the fourth paragraph has been changed from "In Japan, easypod(R) will be launched in September 2009" to "In Japan, easypod(R) will be launched in the course of 2009" as originally issued inadvertently. Complete, corrected release follows:
Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Merck Serono Growth Hormone Injection Device easypod(R) Approved in JapanSeptember 15th, 2009 GENEVA - Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Easypod(R) was developed for exclusive use with cartridges of Saizen(R) (somatropin), Merck Serono's human recombinant growth hormone for the treatment of growth hormone deficiency. GONAL-f Approved in Japan for Ovulation Induction in Infertile WomenJuly 15th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of GONAL-f(R) (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic- pituitary system or polycystic ovarian syndrome. GONAL-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility. Merck Serono Launches "Global Fertility Academy" to Provide Education and Training for the Treatment of InfertilityJune 30th, 2009 GENEVA, Switzerland -
- Global Fertility Academy Delivers Valuable Educational Tools Aiming at Increasing Expertise and Maximizing the Success Rate of Treatment
- Web-based e-Learning Modules Complemented by Individualized Practical Training Sessions at Leading Fertility Centers Worldwide
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the Global Fertility Academy, the first global professional educational program in fertility run by worldwide leading experts in this area.(1) Specifically developed for physicians active in treating infertility, such as reproductive endocrinologists, obstetricians/gynecologists and embryologists, the Global Fertility Academy aims at improving their knowledge of clinical standards in fertility and maximizing the success rates of treatment by providing valuable educational tools and sharing best practices. The Global Fertility Academy is available to healthcare professionals outside of the United States and Great Britain. First Phase III Clinical Trial Results of Safinamide in Advanced Parkinson's Disease to Be Presented at the Movement Disorder Society 13th International CongressJune 2nd, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that detailed results of the first Phase III clinical trial of safinamide as adjunctive treatment in mid- to late-stage Parkinson's disease (PD) (Study 016) will be presented at the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders to be held in Paris, France, from June 7-11, 2009. Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases ManagementMay 27th, 2009 LYONS, France - Poxel SAS is Set up in Lyons - France
Poxel is a research integrated pharmaceutical Company (RIPCO), spun out from Merck Serono a division of Merck KGaA, Germany, following the decision of Merck Serono to no longer invest in diabetes research and development. It aims to advance promising assets for cardio-metabolic diseases (with a primary focus on Type 2 diabetes) from Research to Phase 2 Clinical Proof-of-Concept, before out-licensing these projects to major pharmaceutical companies. Merck Serono Committed to Investing in Innovation in the Fertility AreaMay 17th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe. "Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Dr. Merck Serono: New Phase III Data for Cladribine Tablets to be Presented at the American Academy of Neurology 61st Annual Meeting in April 2009March 29th, 2009 GENEVA, Switzerland - CLARITY (CLAdRIbine tablets Treating MS OrallY) Study Data to be
Presented as Late-Breaking Oral Presentation
GENEVA, Switzerland, March 30 /PRNewswire/ --
Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that the American Academy of Neurology (AAN) has accepted a
late-breaking abstract regarding cladribine tablets, its oral investigational
treatment of multiple sclerosis, for an oral presentation at the AAN 61st
Annual Meeting in Seattle. The abstract is entitled "Results from the CLARITY study: a
Phase III, randomized, double-blind study to evaluate the safety and efficacy
of oral cladribine in relapsing-remitting multiple sclerosis". Merck Serono Launches Strategic Venture Capital FundMarch 22nd, 2009 GENEVA, Switzerland - New Venture Capital Fund Will Invest in Biotech Start-up Companies
Focused on Merck Serono's Core Therapeutic Areas
Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today the formation of 'Merck Serono Ventures', a strategic,
corporate venture capital fund to invest in emerging biotechnology companies. The fund will support biotech start-up companies that have the potential to
provide innovative products in Merck Serono's core therapeutic areas, in
particular in Neurodegenerative Diseases, Oncology and Autoimmune &
Inflammatory Diseases.
Related News German drug, chemical maker Merck second quarter net profit falls 48 percent to euro109 millionJuly 24th, 2009 Merck Q2 net profit falls 48 percent to euro109 MFRANKFURT — German drug and chemical maker Merck KGaA said Friday its second quarter net profit fell 48 percent as higher research costs and one-time effects from the acquisition of Serono weighed on the bottom line. The Darmstadt-based company reported a net profit of euro108 million ($153 million) in the April-June period compared with euro207 million a year earlier. Low thyroid activity may actually be a sign of longevityJune 19th, 2009 NEW DELHI - Gaining weight and losing hair? Well, chances are that you will live longer, say researchers. According to Dr Martin Surks and colleagues at the Montefiore Medical Center and the Albert Einstein College of Medicine in New York, low thyroid activity may hold the key to a long life. Schering-Plough shareholders back $41.1 billion acquisition by partner Merck & Co.August 7th, 2009 Schering-Plough shareholders OK purchase by MerckTRENTON, N.J. — Shareholders of drugmaker Schering-Plough almost unanimously support being bought by bigger New Jersey neighbor Merck. Merck and Schering-Plough say antitrust regulators want more details on $41.1B combinationJune 22nd, 2009 FTC requests more info from Merck, Schering-PloughNEW YORK — Drugmakers Merck and Co. and Schering-Plough Corp., which are in the process of a $41.1 billion tie-up, said Monday the Federal Trade Commission has asked for more information about the deal. Merck, Portola Pharmaceuticals sign deal worth up to $420 million to develop anticlotting drugJuly 9th, 2009 Merck, Portola in $420M deal for anticlotting drugWHITEHOUSE STATION, N.J. — Merck & Co. German pharma, chemical company Merck sees 1st-quarter net profit drop 76 percentApril 27th, 2009 Merck 1Q net profit falls 76 percentFRANKFURT — German pharmaceutical and chemical company Merck KGaA said Monday that its first-quarter net profit dropped by 76 percent as demand for chemicals in particular declined. Darmstadt-based Merck said net profit for the January-March quarter fell to euro57 million ($75 million) from euro239 million a year earlier. Merck to structure itself into 5 units following close of $41.1 billion Schering-Plough dealAugust 31st, 2009 Merck to form 5 divisions after Schering buyoutNEW YORK — Richard T. Clark, current president and CEO of Merck, says the company will restructure into five divisions after it completes the buyout of rival Schering-Plough for $41.1 billion. Drugmaker Merck seeks EU approval for $41B acquisition of Schering-Plough, expects ruling soonSeptember 21st, 2009 Merck seeks EU approval to buy Schering-PloughTRENTON, N.J. — Drugmaker Merck & Co. Shareholders of Merck, Schering-Plough to vote on combination, would create No. 2 drugmakerAugust 7th, 2009 Merck takeover of Schering-Plough up for voteTRENTON, N.J. — Shareholders will decide Friday whether two New Jersey drug companies will become the world's second-biggest drugmaker. Sanofi-Aventis to buy out partner Merck from Merial joint venture for $4 billion in cashJuly 30th, 2009 Sanofi-Aventis pays Merck $4B for share in MerialPARIS — Pharmaceuticals company Sanofi-Aventis SA said Thursday it has agreed to pay $4 billion in cash to U.S. drugmaker Merck & Co.
|
|
